Leading Pharmaceutical Innovation : Trends and Drivers for Growth in the Pharmaceutical Industry

Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business pra...

Full description

Main Authors: Gassmann, Oliver, Reepmeyer, Gerrit (Author), von Zedtwitz, Maximilian (Author)
Corporate Author: SpringerLink (Online service)
Format: eBook
Language:English
Published: Berlin, Heidelberg Springer Berlin Heidelberg 2008, 2008
Edition:2nd ed. 2008
Subjects:
Online Access:
Collection: Springer eBooks 2005- - Collection details see MPG.ReNa
LEADER 03642nmm a2200397 u 4500
001 EB001865170
003 EBX01000000000000001029261
005 00000000000000.0
007 cr|||||||||||||||||||||
008 190425 ||| eng
020 |a 9783540776369 
100 1 |a Gassmann, Oliver 
245 0 0 |a Leading Pharmaceutical Innovation  |h Elektronische Ressource  |b Trends and Drivers for Growth in the Pharmaceutical Industry  |c by Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz 
250 |a 2nd ed. 2008 
260 |a Berlin, Heidelberg  |b Springer Berlin Heidelberg  |c 2008, 2008 
300 |a XVI, 186 p. 47 illus  |b online resource 
505 0 |a Key to Success in the Pharmaceutical Industry -- The Industry Challenge: Do You Really Want to Be in This Business? -- The Science and Technology Challenge: How to Find New Drugs -- The Pipeline Management Challenge: How to Organize Innovation -- The Internationalization Challenge: Where to Get Access to Innovation -- Management Answers to Pharmaceutical R&D Challenges -- Future Directions and Trends 
653 |a Economic policy 
653 |a Public health 
653 |a Pharmacy 
653 |a Management 
653 |a Pharmacy 
653 |a Management 
653 |a Industrial management 
653 |a Public Health 
653 |a R & D/Technology Policy 
653 |a Innovation/Technology Management 
700 1 |a Reepmeyer, Gerrit  |e [author] 
700 1 |a von Zedtwitz, Maximilian  |e [author] 
710 2 |a SpringerLink (Online service) 
041 0 7 |a eng  |2 ISO 639-2 
989 |b Springer  |a Springer eBooks 2005- 
856 |u https://doi.org/10.1007/978-3-540-77636-9?nosfx=y  |x Verlag  |3 Volltext 
082 0 |a 658.514 
520 |a Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia. "One way we try to foster innovation - both the technological innovation and the organizational innovation - is to align our business objectives with our ideals." Dr. Daniel Vasella, CEO, Novartis International "Pharmaceutical innovation is in crisis. The industry will have to change both its innovation processes and its business models in order to reverse these trends and prosper in the future. Professors Gassmann, Reepmeyer and von Zedtwitz have marshalled together an impressive array of research in one volume. This book should prove to be an indispensable resource for all participants in the pharmaceutical industry." Prof. Henry Chesbrough, Executive Director, Center for Open Innovation, Haas School of Business, University of California, Berkeley "It´s time for a paradigm shift in pharmaceutical R&D. This book will tell you why." Dr. Goetz Baumann, Business Unit Manager, Hoffmann-La Roche (Germany) "This book offers a fact based, comprehensive insight to the increasing challenges of today`s drug development. Well worth reading not just for newcomers to the industry but also for industry professionals who want to understand the big picture". Dr. Pius Renner, Head of Strategic Planning and Portfolio Management in Development, Novartis Pharma